According to IQVIA MAT July 2025 data, Rivaroxaban for Oral Suspension, 1 mg/mL (RLD Xarelto) had estimated annual sales of ...

Shares of a company manufacturing niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service, hit a 5 percent upper circuit, after EMA granted initial ...

Indoco Remedies Ltd., a fully integrated, research-oriented pharmaceutical company, announced final approval of the company’s Abbreviated New Drug Application (ANDA) for rivaroxaban tablets USP, 2.5 ...

--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared to rivaroxaban (Xarelto) was even greater in patients ≥75 ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. HealthDay News — Subcutaneous injection of abelacimab results in ...

PM, Shilpa Medicare shares continued to trade 2.04 per cent higher at ₹833.95 per share. In comparison, BSE Sensex was trading flat at 82,176.17 levels.

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It increases the risk of stroke because blood clots can form in the heart and ...

THURSDAY, Jan. 23, 2025 (HealthDay News) — Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...